IGHE and ovarian carcinoma: The antitumour activity of hMOv18 IgE was superior to the equivalent hMOv18 IgG in a syngeneic rat model, and in two human ovarian carcinoma xenograft mouse models reconstituted with human immune cells.8, 9, 10, 11, 12 In preparation for a clinical trial of hMOv18 IgE, we hypothesized that an immunocompetent rat model would provide the most comprehensive evaluation of safety and efficacy.